Aspire Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Aspire Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-71	Closed	-$6K	–	200
2022 Q3	$6K	Hold	71	–	–	0.01%	152
2022 Q2	$5K	Hold	71	–	–	﹤0.01%	163
2022 Q1	$6K	Hold	71	–	–	﹤0.01%	159
2021 Q4	$8K	Buy	+71	New	+$8.56K	0.01%	158

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Aspire Wealth Management's XBI Position: Q4 2022 in Review

Aspire Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 71 shares — an estimated $6K sold.

Aspire Wealth Management first reported a position in XBI in Q4 2021 and held it in 4 quarters. The position peaked at $8K in Q4 2021. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Aspire Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
Aspire Wealth Management sold 71 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $6K.
Aspire Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 4 quarters.
Aspire Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $8K in Q4 2021.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Aspire Wealth Management's 13F filing for Q4 2022, filed 6 Feb 2023.